Polarized light scanner detects Alzheimer’s before symptoms appear

The link between amyloid proteins and Alzheimer's disease is well established. Unfortunately, these structures are often only detectable once the disease has progressed to a relatively late stage. But researchers are developing a noninvasive eye scanning technology that may be capable of detecting Alzheimer's in its earliest stages.

The diagnostic tool uses polarized light to show amyloid protein deposits in the back of the retina, allowing for detection well before symptoms appear.

"Polarization imaging is promising for noninvasive imaging of retinal amyloid deposits as a biomarker of Alzheimer's," said Melanie Campbell, of Waterloo's Department of Physics and Astronomy, who led the research team. "The ability to detect amyloid deposits in the retina prior to disease symptoms may be an essential tool for the development of preventative strategies for Alzheimer's and other dementias."

Being able to identify the amyloid protein gives researchers a quicker start in combating symptoms before they appear. The polarized light scans are as sensitive as other methods and can be done without irritating dyes, making it both cost effective and convenient, with the potential to be used as an in-office screening tool.

"Early diagnosis is important, especially since treatment options are more limited later in the disease," said Campbell. "Widely available, inexpensive, early detection of amyloid would help researchers develop more effective treatments before the onset of symptoms."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.